What changed in psilocybin law

Canada's entry said nobody in Canada buys psilocybin legally, no license to sell it has ever existed, and a doctor asks for an individual section 56 exemption. Health Canada's pages and the Controlled Substances Regulations say otherwise. Under the Special Access Program the manufacturer sets the price and in some cases the patient or their family pays, licensed dealers sell to practitioners named in a letter of authorization, and patients apply for section 56 exemptions themselves, with a practitioner's support. The entry also dated the Federal Court of Appeal's judgment in Toth v Canada, 2025 FCA 119, to 26 June 2025; the judgment was delivered on 18 June 2025. Its account of the case now sits under History, without four details that the judgment does not bear out as written or that no source confirms.

Correction. An update published here on 14 September 2026 said written comments to the FDA about its public hearing on psychedelic medicines could be sent until 6 October 2026. The deadline was 11:59 p.m. Eastern on 5 October 2026, as the hearing notice and the FDA's meeting page both say; the date we published came from a database field kept in universal time, which runs four hours ahead of Eastern time. The same update said the hearing took place on 14 September without citing a source. The FDA's own recording of its live webcast shows that it did. Nothing about federal law has changed.

Correction. An update dated 15 September 2026 recorded the fees in Oregon's proposed psilocybin rules, among them a facilitator licence rising from $2,000 to $4,000 a year and service center and manufacturer licences rising to $20,000. Those amounts were already public in the proposed rule text Oregon filed with the Secretary of State on 28 August 2026, which an earlier update records; 15 September was the day of the first public hearing and the day the figures reached us. Oregon has since dropped the increases, and its legal status is unchanged.

Correction. Canada's entry said that since 1 October 2026 the Special Access Programme route had "a new legal footing", and that access continues under the new Controlled Substances Regulations. That claimed too much. The Programme's letter of authorization is still issued under the Food and Drug Regulations, as it was before. What the new regulations supply since 1 October is the authority for what the practitioner and the licensed dealer named in that letter may do with the drug. Until then that part was covered only by an exemption dating from January 2022.

A pending Senate bill that names psilocybin has been added to this entry. S. 4031 would have the Department of Veterans Affairs designate at least five centers of excellence for therapies that include psilocybin. It was introduced in March 2026, has not moved out of committee, and does not change psilocybin's legal status.

New Mexico's entry is corrected on two points. Applications are open for psilocybin growers but had not yet opened for testing laboratories when the Department last posted, on 18 September 2026. The hearing on the proposed patient rule was set for 2 October 2026, and the Department had published nothing further by 5 October. Patients still cannot enroll.

New Mexico has opened applications for psilocybin testing laboratories. The Department of Health said on 5 October 2026 that its online portal for laboratory permits is open, under the producer and laboratory rule that took effect in June. A laboratory permit is for testing psilocybin grown for the programme. It does not let anyone treat a patient, because the rule that would enroll patients and certify clinicians is still a proposal.

Canada's new Controlled Substances Regulations came into force on 1 October 2026 and now supply the authority for what the practitioner and the licensed dealer may do with psilocybin. Access through the Special Access Programme still opens with a letter of authorization issued under the Food and Drug Regulations, as it did before. Health Canada said it would revoke the older exemption on the same day. Its website had not been updated to confirm that when this entry was reviewed on 5 October 2026.

Analysis: Canada's approval numbers

Portland's City Council voted on 30 September 2026 to make the personal, non-commercial use of natural psychedelics, including psilocybin mushrooms, a low priority for law enforcement. The ordinance takes effect on 30 October 2026, excludes peyote and allows no sales. Oregon state law is unchanged.

The Netherlands entry was read against the newest version of the Opium Act, in force since 17 September 2026. That amendment added three synthetic stimulants to List I. Mushrooms stay banned, and truffles still appear nowhere in the Act.

The United Kingdom entry no longer says research licensing was eased in 2025. Ministers agreed to a pilot in principle and have not yet changed the rules. Psilocybin mushrooms remain Class A.

Illinois was re-checked on 28 September 2026. Its psilocybin advisory board bill is still parked in the House, the licensing bill has never reached a floor vote, and the entry now cites the statute that keeps psilocybin in Schedule I.

Michigan's entry now cites the section of state law that actually lists psilocybin in Schedule 1, and separately the penalty for using it. Nothing about the state's status has changed.

New York's four psilocybin bills were re-read on 28 September 2026 and none has moved since August. Psilocybin is still a Schedule I substance in the state.

A note on method for the entry of 22 September 2026: the Oregon Health Authority statement it reports was read in full on 28 September 2026, as the HTML its web page served. Nothing in that entry changes, and Oregon's legal status is unchanged.

Rhode Island's entry now cites the law in force. The state repealed its own drug schedule in February 2025 and since then has controlled every substance on the federal list, where psilocybin remains in Schedule I. Its legal status is unchanged.

South Dakota's entry was read against the state's code on 28 September 2026 and every date in it holds. The trigger law now sits in the codified drug schedules, and psilocybin remains in Schedule I because the FDA has approved no psilocybin drug product.

Utah's entry now cites the renumbered sections of the state's drug law, and says when the overdue-report finding was last seen, since the registry that showed it can no longer be reached. The hospital-based psilocybin authorization is unchanged.

Virginia's two trigger laws were re-read on 28 September 2026 and nothing has fired. No federal order has been published for them to act on, and psilocybin is still listed in Schedule I.

The District of Columbia entry was re-read against the Council's own law library on 28 September 2026. Initiative 81's rule is unchanged: police treat adult non-commercial use of psilocybin as one of their lowest priorities.

Oregon will not raise psilocybin licence fees after all. On 22 September 2026 the Oregon Health Authority said it is dropping the rulemaking that proposed doubling the main licence fees from 1 January 2027 and will not adopt the increases, so the fees businesses pay today stay as they are. The changes in that package that had nothing to do with fees go into a new rulemaking the authority plans to start in the coming weeks, aiming for them to take effect on 15 January 2027. Oregon's legal status is unchanged.

Canada's entry was reviewed before new federal regulations take effect on 1 October 2026, and two details were corrected. The regulations were registered on 28 November 2025, not 17 December, which is when they were published. And the regulations do not themselves cancel the exemption that links psilocybin to the Special Access Programme: Health Canada has said it will do that on the same day. The route continues under the new regulations, and individual section 56 exemptions are unaffected. We will check again once 1 October has passed.

Health Canada has released how many psilocybin applications its Special Access Program received, approved and denied each year. In a reply tabled in the House of Commons on 21 September 2026 it reported none before 2022, then 71 applications in 2022 (58 approved, none denied), 152 in 2023 (112 approved, 5 denied), 177 in 2024 (119 approved, 21 denied), 109 in 2025 (51 approved, 2 denied) and 30 in 2026 (14 approved, none denied). The figures leave out requests that were cancelled, withdrawn or incomplete. Canada's legal status is unchanged.

Analysis: Canada's approval numbers

Ecuador's entry now cites a government source for the first time: article 364 of the Constitution, in the National Assembly's own text, which bars criminalizing people who use drugs. The decree that repealed the possession thresholds, the criminal code articles and the 2023 court resolution are still not sourced to a government document, and the entry says so.

This entry no longer says that wellness clinics were planned for patients in Saint Vincent and the Grenadines. Nothing we can cite supported it. We also checked the right part of the government this time: the Bureau of Standards named as the licence issuer sits under the Ministry of Agriculture, whose website we had never searched. On 21 September 2026 it returned nothing for psilocybin, nothing for psychedelic and nothing for the companies named in the announcements, while returning results for arrowroot and for the Bureau itself. The country's legal status here is unchanged, and so is our low confidence in it.

Colorado was checked again on 21 September 2026 and nothing has moved. The state's rulemaking on House Bill 26-1325 is still headed for a stakeholder meeting on 30 September and a final hearing on 4 November 2026, and the laws behind the program read as this entry says.

Massachusetts was checked again on 21 September 2026 and nothing has moved. The bill that carried a supervised psilocybin pilot through the House is still with a conference committee, which has not reported, and the four standalone bills are where they were in July.

An update published here on 17 August 2026 described the Department of Health's psilocybin programme page as one that had not been updated. That judgement was reached by measuring the page's underlying code, which never contains its announcements: those are loaded from another service when a reader opens the page. Read in a browser today, the panel carries dated departmental notices going back to June 2026, including the opening of producer applications and the notice of the 2 October hearing. We cannot say what it displayed back in August, because the panel keeps no history of its own changes. The sources this record relies on do not change, and New Mexico's legal status is unchanged.

Washington was checked again on 21 September 2026 and nothing has moved. The 2023 law behind the University of Washington pilot, and the state statutes that keep possession a gross misdemeanor, read as this entry says.

New Mexico has issued its first psilocybin producer permit. The Department of Health said on 18 September 2026 that it has permitted Sacred Alto Spores, that the grower is starting operations, and that it expects to open laboratory permit applications shortly. A permitted grower may only supply practitioners and healing centers once those are certified, and the rule that would certify them is still a proposal going to public hearing on 2 October 2026. No patient can be treated under the programme yet.

This entry said a 2023 decree ended police fines for drug use in Colombia. It did not: the decree repealed a police procedure, and the Police Code still fines consuming drugs near schools, in parks and in other public places, within limits the Constitutional Court has set. The entry also now explains which court rulings protect a psilocybin user.

The entry now names the Colombian law that lists psilocybin, Ley 43 de 1980, and dates the 2026 Ministry of Health resolution that keeps it on the national list.

The entry now lists a Senate bill that would provide for the seizure and destruction of drugs, including the personal dose.

This entry described possession for personal use in Costa Rica as lawful. It is not: the drug statute sets no criminal penalty for it, but the law still treats drug use as illicit. The wording is corrected. The rest of the entry, including the absence of any quantity threshold, was re-checked against the statute and stands.

Costa Rica's drug law is now cited by its correct name, Ley 7786 as rewritten in full by Ley 8204 in 2002, with a link to the current official text. This entry also names the article of the General Health Law that prohibits personal drug use, and now says that growing or producing drugs is punished whatever the purpose, and that the treatment article covers minors in private places as well.

Costa Rica's official list of controlled substances names the compounds psilocybin and psilocin and has no entry for mushrooms, and this entry now says so.

Italy's entry was corrected. It had described the 2006 health ministry decree as setting a daily limit for psilocybin and psilocin and none for the mushrooms. The decree sets a threshold of 300 mg each, worked out from an average single dose, and measures mushrooms by the psilocybin and psilocin they contain; the entry now also cites the 2014 decree-law that put that decree back into effect after the Constitutional Court's judgment that year. The legal status is unchanged.

Portugal changed its rule on drug quantities in October 2023, and this entry had not caught up. The 10-day supply is no longer a hard limit. Carrying more is treated as a sign the drugs may not be for personal use, and once personal use is shown, the case still goes to a Dissuasion Commission. The entry now says so and cites Law 55/2023.

The entry now names where Portuguese law lists psilocybin: Table II-A of Decree-Law 15/93, republished in May 2026. It also notes that Portugal's official table of average daily doses, a reference for what counts as a 10-day supply, gives no figure for psilocybin.

The entry now lists two bills before Portugal's parliament that would tighten the 2023 possession rule for all drugs, including psilocybin. Neither has had a plenary vote.

Oregon's proposed rule text now puts figures on the fee increase. A facilitator licence would cost $4,000 a year, up from $2,000, service center and manufacturer licences would double to $20,000, and a worker permit would go from $25 to $200, while the reduced fees now available to nonprofits, veterans and applicants on public benefits would be removed. The state's filed notice says the increases would take effect on 1 January 2027, with laboratories paying the higher fee only from 2029, and it expects the change may shrink the number of licensees. Nothing is final until Oregon adopts the rules, and written comments close on 21 September 2026.

Since then: Corrected on 6 Oct 2026: these amounts were filed on 28 Aug 2026. The increases were dropped on 22 Sep 2026.

The FDA held its public hearing on psychedelic medicines on 14 September 2026. A week later the agency had published nothing from it: the docket still contains only the notice that called the hearing. You can still write to the FDA about it until 6 October 2026; a later deadline than the one for asking to speak, which closed in August; and 110 people and organisations had done so by 15 September. Nothing about federal law has changed.

Since then: Corrected on 6 Oct 2026: written comment closed at 11:59 p.m. Eastern on 5 October, not 6 October.

Maryland's Schedule I keeps no list of drugs of its own. It takes in whatever the federal government schedules, and that is how psilocybin is controlled here. The record now says so, and names the sections that make possession and distribution offences.

An update published here on 25 August 2026 said New Mexico had until the end of 2026 to have its medical psilocybin programme running. The Medical Psilocybin Act sets one implementation date and it is 31 December 2027. December 2026 is the date the Department of Health has said it aims for, and this record's law section has always described it that way. New Mexico's legal status is unchanged and no date in that law section moves.

Two Oregon licensing figures are corrected. The state approved 377 facilitator licences and 25 service center licences during 2025, and those figures count approvals granted across the year. They are not a roster of licences held at its end, and the health authority publishes no year end count. How many people received services is unchanged, at 5,935 in 2025 and 952 in the first quarter of 2026. Oregon's legal status is unchanged.

Colorado's Natural Medicine Division has opened rulemaking to carry out House Bill 26-1325, with a stakeholder meeting on 30 September and a final hearing on 4 November 2026, when written comments also close. The proposed topics include temporary premises permits, limited sales licences and testing waivers. The Division also confirms that its emergency rules of 12 August created a limited sales licence for healing centers, and the application form is now available.

The federal record's notes were corrected. The April executive order's rescheduling review attaches only once a drug completes Phase 3 trials for a serious mental health disorder, and it sets no deadline; the earlier wording read as an overdue action. DEA rescheduling actions published since the order concern marijuana products and three insomnia drugs and do not mention it. Document counts were updated as of 1 September 2026. The legal status is unchanged.

Oregon's psilocybin and medical marijuana programmes are now one section of the state health authority. On 1 September 2026 the Oregon Health Authority merged Oregon Psilocybin Services and the Oregon Medical Marijuana Program into a Medical Cannabis & Psilocybin section led by the psilocybin programme's existing manager, and the state says services and processes carry on without disruption while forms and web pages take the new name over the coming months.

New Mexico's record was wrong about how far the state had got, and this corrects it. The rule that licenses psilocybin growers and testing laboratories was not still a proposal: it took effect on 23 June 2026, which is why the Department of Health was able to start taking applications from growers in August. The rule covering patients, clinicians, facilitators and healing centres has come back from being cancelled and now has a public hearing set for 2 October 2026. New Mexico can license a grower today, but still not a clinician and still not a patient.

Croatia's record gave one to twelve years for selling. A November 2025 amendment raised the minimum to three, and the entry published in August had missed it. The possession fine is now shown in euro, the currency it is actually imposed in. The record also now says that a first offence can be met with treatment instead of a fine, and that giving mushrooms to someone else is a separate crime.

Croatia's record cited the wrong law. The 2011 Criminal Code it pointed to still made possession a crime; the act that changed that was a 2012 amendment. Both cited sources are now the official gazette texts that do the work. The decriminalized status is unchanged.

Two penalty corrections. The one to twelve year sentence covers selling, not growing, which carries six months to five years. The possession fine comes from a different act and is set in kuna, so the euro figure shown before was low. The record now also states that growing mushrooms counts as producing a drug.

Oregon took public comment on a petition to change the rule that governs how psilocybin facilitator training programmes get their curriculum approved. The comment period closed on 29 August 2026. This is a separate track from the state's larger annual rule changes.

Removed an unverified patient count and a related safety statement from this entry. No official Australian publication supports them; the regulator releases scheme data only through freedom of information disclosures, which this register has not yet read. The scheme's legal status is unchanged.

Brazil's entry now explains what the drug statute actually does. It prohibits no substance by name; it defines a drug as whatever appears on a list kept by the health agency, which is why an unlisted mushroom containing a listed molecule is a genuinely contested question there. The entry also now says that possession, and growing for personal use, carry no prison sentence in Brazil. The status is unchanged.

Oregon has filed the formal notice for its 2026 psilocybin rule changes. The proposed rules would double licence fees and end the reduced fees used by nonprofits, veterans and people receiving SSI or SNAP, which accounted for about thirty two percent of licence transactions this biennium. The state says the programme was meant to pay for itself and does not. Comments close on 21 September 2026, with public hearings on 15 and 16 September. The same rules carry House Bill 4040, which would let Oregon recognise facilitator training approved by other states.

Since then: The increases were dropped on 22 Sep 2026.

New Mexico has proposed a new rule setting out how patients enrol in its medical psilocybin programme and how clinicians, facilitators, healing centres, other approved locations and training programmes are approved. A public hearing is set for 2 October 2026 in Santa Fe, with a video conference and telephone option, and written comment is also accepted. The state has until the end of 2026 to have the programme running.

Oregon has opened a public comment period on new psilocybin rules that would change all licence fees and end reduced fees. Comments run from 1 to 21 September 2026, with public hearings on 15 and 16 September. The state gives rising costs and programme sustainability as the reason.

Since then: The increases were dropped on 22 Sep 2026.

New Mexico's education committee has set out what it thinks training should require before someone can work in the state's medical psilocybin programme: eight hours for a doctor who certifies that a patient qualifies, and roughly two hundred hours for the licensed providers and facilitators who sit with patients through a session. These are recommendations to the health department, and the rule they would go into goes to public hearing on 2 October 2026.

New Mexico's own education committee and its health department do not agree about how facilitators should be trained. They want almost exactly the same number of hours, so this is not an argument about cost. They differ on what the hours are made of: the department would have trainees spend sixty of them on a general practicum with real patients and add ten hours of mentorship after graduation, while the committee would have them spend twenty-four hours with well volunteers and eighteen presenting cases to a consultation group, with no mentorship requirement.

Australia's entry now names the provisions that actually limit prescribing, Appendix D clause 9 of the Poisons Standard and subsection 19(5) of the Therapeutic Goods Act, and records an application to allow psilocybine for existential distress at the end of life. A delegate decided on 29 May 2026 that the current scheduling remains appropriate, and a final decision is still to come. Psilocybin remains prescribable only by an authorised psychiatrist and only for treatment-resistant depression.

Denmark's entry pointed at an executive order that stopped being current in 2020. The order in force is now cited, and the listing itself is unchanged: mushrooms and their spores have been controlled since 2001.

North Macedonia's entry had no official source and applied one article's prison range to two different offenses. The gazette has now been read: the range belongs to the supply offense, the separate offense of enabling use carries one to five years, and a 2023 amendment says a person holding drugs for personal use is not to be punished.

Norway's entry said the 2025 drug reform was in effect. It is not: the Act has passed and been promulgated, but commencement is left to the King and has not been set, so nothing in it has started.

California's 2025 research law is broader and shorter-lived than this entry said. AB 1103 speeds up state review of research using any Schedule I or Schedule II drug, psilocybin among them, rather than psychedelics specifically, and the fast-track expires on 1 January 2028.

Indiana's psilocybin research fund is funded at $300,000 a year, $600,000 over the two-year budget, and the money comes from the state's opioid settlement account rather than general tax revenue. The amount and its source are now recorded from the budget act itself.

New Mexico has a $630,000 fund to help patients pay for psilocybin treatment, and a committee has now set out how it would work: travel costs for patients living more than fifty driving miles from a treatment centre, and vouchers on a sliding scale that gives full help at about twice the federal poverty level and nothing above three times it. The committee expects more people to qualify than there is money for. This is a recommendation, not a benefit anyone can claim yet.

Argentina's entry now cites the instrument that actually lists psilocybin. The statute it cited before, Law 23.737, never names the substance: it defines controlled drugs by reference to lists that the executive sets by decree, and the decree in force is Decree 122/2026.

Armenia's entry now cites the articles that actually carry the law: Article 396 of the 2021 Criminal Code for the criminal tier and Article 44.1 of the Code of Administrative Offences for the administrative one, replacing an insider-dealing article and an article repealed in 2004. The government decision that lists psilocin and psilocybin is cited for the first time, and the penalty range is restated from the statute.

Canada's entry now cites the regulation that actually carries the 1 October 2026 date, and corrects what it said would happen next. The exemption is being folded into new regulations rather than simply ending, so the Special Access Programme route is carried forward past that date.

Czechia's entry now cites a version of the law that can be read and checked, and records a limit it had missed: treatment is confined to psychiatric hospitals run directly by the Ministry of Health, and any other facility needs a permit.

Germany's entry was a year out of date. The regulator lists one psilocybin programme, running from 18 June 2026 to 17 June 2027 at a single institute in Mannheim for treatment-resistant depression, and the entry now says that instead of describing a national scheme.

Nepal's entry no longer says only that the law is evolving. It now states what the Narcotic Drugs (Control) Act actually lists, cites the government's own consolidated text and the drug regulator's import list, and explains that psilocybin's position rests on being left out of both rather than on any permission.

The Netherlands entry no longer says truffles are sold in licensed smart shops or that they were explicitly excluded from the 2008 ban. The Opium Act contains no smart-shop licence and never mentions truffles at all, so they fall outside it rather than being carved out of it.

Switzerland's entry now cites the schedule that actually names psilocybin, rather than resting only on the Narcotics Act article, which does not. Nothing about the law itself has changed.

Thailand's entry now carries the full set of penalties the Thai FDA publishes, including the fine attached to the five year term and the separate commercial and distribution band it had omitted. Nothing in Thai law has moved; the widely repeated 2026 reform claims trace only to content farms.

Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.

Colorado's entry no longer calls healing centers 'in development': state-licensed centers have been operating since 2025.

Connecticut's entry now cites the text of the act itself rather than a bill tracking page that never mentioned psilocybin. Nothing about the law changed; the citation now supports what the entry says.

Louisiana's psychedelic-assisted therapy initiative is law and has been in force since 1 August 2026. The entry still described it as a bill awaiting the governor's signature.

Minnesota did enact psilocybin language in 2026 after all. It is not access: a cannabis act signed in May requires the state to publish a report by 15 January 2027 on how a psilocybin therapeutic use program could work. We had recorded that no psilocybin provision passed.

Montana's entry now says when its no-pending-legislation claim was last checked: the 1 Aug 2026 review. The legislature meets in odd-numbered years, so nothing can advance in regular session this year.

New Mexico's record now cites the rulemaking page rather than a programme page that has not been updated, and says plainly that the producer and laboratory rule is only proposed and the patient and practitioner rule was canceled and is to be rescheduled. The 2026 budget act, signed in March, is added: it funds the treatment equity fund and a university research programme and gives the Health Department another year to spend its 2025 start-up money.

Ohio's entry now dates its no-bills-with-movement claim to the 16 Aug 2026 review. The one cited proposal, listed as HB 249 of 2025, still shows no committee movement.

Oregon's entry now cites the session law rather than a bill overview page that did not carry the dates the entry published. The facts are the same; the citation now proves them.

Utah's entry overstated two things. The law allows a wider class of health systems than we described, following a 2026 renumbering, and we called the pilot operational when no state record shows that it is. The report the Legislature required by 1 July 2026 is registered as overdue and unfiled.

The British Virgin Islands entry now says plainly which part of its reading is ours. The statute lists psilocin; the view that unlisted fresh mushrooms leave a real ambiguity comes from comparing the territory's law to England before 2005, and no local instrument or court has said it. Confidence has been lowered accordingly.

Pakistan's entry quoted a Schedule-I heading that does not appear in the Act, and cut off its quotation of section 6 one clause early. Both are corrected against the Government of Pakistan's own consolidated text, which also carries a 2022 amendment the entry had never mentioned. Psilocybin's listing itself is confirmed.

Australia's entry now cites the national Poisons Standard rather than a Victorian state page. What the law says is unchanged.

Austria's entry was checked again against the statute itself and nothing had changed. The law names psilocybin mushrooms in its own words.

Belgium's entry pointed at the wrong article for the probation route open to people caught with drugs for their own use. It is article 9, not article 9bis, and the entry now says so. The penalties are unchanged.

Bolivia's entry now cites Bolivia's own official consolidated law rather than a third-party database, and names the 2017 law whose list actually covers psilocybin. A cultivation penalty the entry had cited rests on a cross-reference repealed in 2017 and has been removed. Psilocybin remains illegal.

Brazil's entry now cites the version of the controlled-substances list actually in force, and records that in August 2025 the Superior Court of Justice held that selling psilocybin mushrooms is drug trafficking even though the mushroom itself is not on the list. The status is unchanged.

Canada's entry now shows that the exemption connecting psilocybin to the Special Access Programme is revoked on 1 October 2026. The route is open until then.

Czechia's entry now cites the adopted regulation rather than the draft that was notified to the EU, and records which specialists may prescribe.

Denmark's entry said no bill was pending. A resolution proposal on psychedelics, B 5, had in fact been tabled and then lapsed when the session ended in March 2026, and the entry now records it. The list of banned substances also covers spores, which the entry had not mentioned.

Finland's entry had no primary source behind it. The Narcotics Act and the decree that lists psilocybin are now cited directly, and both say what the entry already said.

France's entry quoted a 500 euro fixed fine that was announced but never enacted. The statute sets 200 euros, reduced to 150 and raised to 450, and the entry now matches it.

Iceland's entry was checked again against the regulation that lists the substances. It bans psilocybin and psilocin outright, with no exception for freshly picked mushrooms, exactly as the entry says.

Jamaica's entry is flagged as not yet checked against the text of the Dangerous Drugs Act. What it says is unchanged; how confident the register is in it has been lowered.

Jamaica's entry has now been checked against the text of the Dangerous Drugs Act itself, which was the outstanding task. Neither the Act nor its regulations mentions psilocybin or mushrooms anywhere, so the status stands and confidence has been restored. The entry now says plainly that this is legality by omission, not an approved programme.

Lithuania's entry rested on a European agency summary and said the administrative route had been abolished in 2017. Using drugs without a prescription is still an administrative offence there; it is possession that is criminal. The entry now cites the Criminal Code and the substance list directly, and records that spores are covered.

Mexico's entry was checked line by line against the two statutes in force and everything it says about the law holds. One correction: a Senate initiative it described was presented in 2023, not 2024, and the entry no longer claims to know whether it is still alive.

The Netherlands entry was checked again against a newer version of the Opium Act. Mushrooms are still banned and truffles still are not in the Act at all, which is why they remain lawful. Two amendments this year touched other articles.

New Zealand's entry is re-verified against Medsafe's own guidance and two government releases, which date the prescribing pathway to June and July 2025 and confirm that psilocybin remains an unapproved medicine.

North Macedonia's entry is re-checked with no change found. The contradiction between how possession is written and how it is prosecuted stands, and we still have no official text of the Criminal Code to check either against.

Norway's entry described the 2025 drug reform as an agreement between parties. It had already passed the Storting and been promulgated in June 2025, and it is waiting on the King to bring it into force. It keeps the ban in place.

Peru's entry cited a version of the penal code article that had been replaced twice since. The current text is now cited from the official gazette. The list of drugs with a personal-use exemption still does not include psilocybin, so the status is unchanged.

Portugal's entry pointed at a dead source. The law itself has now been read from the official gazette, which confirms the 2001 start date and that cultivation is still a crime. The entry also now says plainly that this is a general all-drug law that never mentions psilocybin.

Sweden's entry was checked again against the statute and against a search of the Riksdag's own document service. The law is unchanged and nothing new has been put before parliament.

Switzerland's entry now reports 686 exceptional authorisations for 2024, 322 of them for psilocybin, citing the Federal Office of Public Health's own figures. It no longer describes these as patients: an authorisation runs about twelve months, covers several treatments and includes continuations of an existing therapy.

The United Kingdom entry was checked again against the Act, the regulations and the ACMD's own 2026 work programme. Psilocybin remains Class A and Schedule 1, and the review the government commissioned in 2025 has not reported.

Uruguay's entry credited the wrong law with the current wording of the drug-possession article; it was last rewritten in 2020, not 1998. The entry now also records the penalty range and notes that the article's only quantity limit applies to marijuana. The status is unchanged.

Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.

Connecticut's expanded pilot program took effect on 1 July 2026, not on the June signing date the entry previously showed. Corrected from the text of the act.

Checked against the enrolled text of the 2025 act. Florida's spore offence and its penalty are as recorded.

Indiana's research fund was paid for by the biennial state budget, not by the standalone bill the entry credited, and the fund now covers ibogaine as well as psilocybin. Corrected from the legislature's own records.

Maine's entry cited the wrong bill paper in the wrong Legislature, and still listed a dead bill as pending. Both fixed, and the law that actually prohibits possession is now named.

A note in Michigan's entry described an old decriminalization bill as an Oregon-style licensing bill and put it in the wrong session. Corrected against the legislature's record.

Mississippi's entry no longer lists the state's 2026 ibogaine research law as pending. It was signed in March 2026 and takes effect on 1 July 2026, and no psilocybin measure is pending.

Missouri's entry now says plainly what happened to the psilocybin study bill. It passed the House in April 2026, sat on the Senate's informal calendar from 7 May, and was never truly agreed before the session ended.

Nevada's entry was checked again on 16 August 2026. The state health department's own page confirms the 2023 working group is a study body. The legislature's website could not be reached, so the bill history is queued for a manual check.

New Hampshire's entry no longer lists HB 1772 as pending. It became law in 2026 as Chapter 333, it covers prescribing ibogaine for investigational use, and no psilocybin measure was enacted. Psilocybin is still a controlled drug in New Hampshire.

New Jersey's entry was checked again on 16 August 2026 and nothing changed. The legislature's website could not be reached, so the pilot programme's paperwork is queued for a manual check.

New York's entry was re-checked against the Senate's own bill pages on 16 August 2026. All four access bills are still in committee without a vote; one of them was amended in May 2026.

North Carolina's entry was checked again on 16 August 2026. The legislature's website blocks our requests, so the record could not be re-read and nothing was changed.

Ohio's entry was reviewed on 16 August 2026 without being re-checked against an Ohio government source, because Ohio's own statute and legislature websites could not be reached. Nothing was changed.

Texas's entry no longer carries an effective date. Texas has no psilocybin access law, so there is no date to give; the prohibition and the ibogaine research programme are unchanged.

Checked against the D.C. Council's own record of the law. Nothing has changed since it took effect in March 2021.

The British Virgin Islands entry pointed at the wrong schedule. The controlled-drug list is Schedule 2, and psilocin sits in its Class A part. The statute was read this time from the government's own live copy.

Poland's entry said the 2005 drug Act lists psilocybin. The Act's annexes have been repealed and the list now lives in a health ministry regulation, which the entry now cites. A separate amendment to that Act was signed in July 2026; it deals with treatment and procedure and leaves the possession offence and the substance lists alone.

Greece's entry named a drug code that was repealed in 2013. The operative law is Law 4139/2013, and the entry now cites it, along with the schedule that still names psilocybin and psilocin. Nothing about the legal status changed.

Canada's record said there were no bills before Parliament. There is one: C-286, a private member's bill introduced on 16 June 2026 that would allow psilocin and psilocybin to be used for medical treatment. It is not scheduled for debate, and the entry now says so.

California's record now lists SB 1224, the Emerging Therapies Research Partnership Act, which names psilocybin among the emerging therapies a state research fund would support in federally registered trials, with a veterans focus. The bill was held in the Assembly Appropriations suspense file on 13 Aug 2026.

Colorado's Natural Medicine Division put an emergency fee schedule for the regulated program into effect on 12 Aug 2026, with permanent rulemaking announced for later this year. The legal status of psilocybin in Colorado is unchanged.

Colombia's entry now cites the Constitutional Court's 1994 judgment directly and dates it 5 May 1994. The rewritten summary explains that no statutory quantity covers psilocybin and that police fines for personal-dose possession ended in December 2023.

Costa Rica's entry now cites Ley 8204 itself and dates its effect to 11 January 2002. The rewritten summary explains that the line between lawful possession and trafficking is a purpose test decided case by case rather than a quantity threshold.

Italy's entry now cites the consolidated Testo Unico directly. The summary lists what article 75 actually reaches and what it suspends, and treats quantity as a circumstance courts weigh rather than a line that decides the case.

Slovenia's entry now cites the classification decree annex directly and corrects the penalty description: a fine and up to thirty days, five for a small quantity, with articles 186 and 187 stated separately.

Spain's entry no longer calls small quantities legal. It describes the public-place administrative fine under Ley Organica 4/2015 and keeps personal consumption outside the criminal code, now citing the consolidated Penal Code as well.

This entry now carries much lower confidence. The licence scheme it describes comes from company announcements, and no government source for it has been found.

Australia's entry no longer calls the country the first to regulate psilocybin. It now says what the rule does instead: an authorised psychiatrist may prescribe it for treatment-resistant depression.

Germany's entry now describes how its compassionate use programme actually works. A sponsor notifies the regulator, which confirms the notification rather than granting an approval, and the confirmation has to be renewed each year.

The Bahamas is now recorded as illegal. A 2024 government order brought psilocybine under the Dangerous Drugs Act, and our earlier reading came from a 2017 version of the Act that predates it.

Canada's record now carries a date it was missing: the exemption that links psilocybin to the Special Access Program is revoked on October 1, 2026, when new regulations take effect.

Czechia's record drops an unsupported claim to be Europe's first such framework, and now states the three conditions the regulation actually names.

Maryland's record now explains something it never said: the state's drug law does not govern the clinical trials that run there. Those answer to federal regulators.

Northampton's date moves from March 18 to April 1, 2021. The city council gave the resolution a first reading in March and adopted it on the second reading two weeks later. Somerville's January 14, 2021 date and Cambridge's February 3, 2021 date were checked against city records and are unchanged. All eight Massachusetts municipal dates now come from municipal records.

Argentina's drug statute still criminalizes possession while courts apply the 2009 personal-use doctrine case by case. Nothing is pending, and the record now cites the law itself.

Alaska's psychedelics ballot initiative is listed as active by the Division of Elections, with petition booklets circulating and a September 2026 filing deadline. The record previously called it failed.

Colorado now lists 47 licensed healing centers as of July 31, 2026, per the state's Natural Medicine Division.

Georgia's veterans psychedelic pilot bill died at adjournment, and a bill number long recorded beside it turned out to be a court-fee act. Nothing is pending; the state's two 2026 psychedelic laws stand.

Hawaii's bill to create a psychedelics study task force died in conference committee at the end of the 2026 session. Nothing is pending.

Illinois's verification marker now reflects the July 2026 re-review, which confirmed the record against the legislature's own status pages.

Iowa's medical psilocybin bill died on the Senate calendar two days before adjournment, after passing the House 84 to 6. Nothing is pending.

Kansas's FDA-trigger psilocybin bill died on the House calendar on Turnaround Day in February, and the legislature has adjourned. Nothing is pending.

Kentucky's 2026 session ended with no psilocybin bill. Nothing is pending.

Maryland's ibogaine research bills died at adjournment and nothing is pending. The state's psychedelics task force now runs through 2027, with a report due this October.

Eight Massachusetts cities and towns have adopted resolutions making enforcement of psilocybin laws a low local priority, three more than this record named. Salem's is dated June 8, 2023, when the City Council adopted a revised resolution after the Acting Mayor vetoed the original.

Montana still lists psilocybin in Schedule I. The legislature does not meet in regular session this year and nothing is pending.

Rhode Island's record now lists H 7925 as pending. The committee's own 2026 agendas show it was never scheduled for a hearing.

Virginia's trigger laws are now recorded as signed on April 6, 2026, per the legislature's own bill histories.

An Irish Seanad bill to decriminalise personal drug possession is at committee stage, and the record now names it. Psilocybin's controlled status is unchanged.

Estonia's recorded maximum fine for small-quantity possession is corrected to 300 fine units, and the record now cites the law itself.

Latvia's record now cites the exact law that makes small-amount possession an administrative offence. The status itself is unchanged.

Ukraine's record now reflects the 2023 reform: first-time possession above the small-amount threshold is punished without imprisonment. Small amounts stay an administrative offence.

Illinois still lists psilocybin as a Schedule I controlled substance. A Senate-passed advisory board bill remains stalled in the House.

The Massachusetts House voted 148 to 2 for a bill carrying a supervised psilocybin pilot. The Senate removed the pilot and the bill is now in conference.

Minnesota's record now lists three more psilocybin bills from the 2026 session. None passed, and the session adjourned in May 2026.

New Mexico's record no longer says $4 million was appropriated for the medical psilocybin program. The enacted act creates two funds that the legislature funds separately.

Rhode Island's pending bill list is cleared. H 7756 was withdrawn in April 2026, and a parallel bill introduced in February 2026 is recorded in the summary.

South Dakota's record no longer lists its enacted trigger law as pending. The law turns on FDA approval alone, not on any DEA action.

Virginia's psilocybin trigger laws are recorded as chapters 305 and 306 and have been in force since July 1, 2026. The trigger has not fired and psilocybin stays in Schedule I.

Washington's record now cites the 2023 session law itself. That act was a partial veto which struck the advisory board and the health department's rulemaking authority, and it took effect July 23, 2023.

Oregon is taking public comment on a petition to change the rule that sets how facilitator training courses are approved. Comments close 29 Aug 2026. The program itself is unchanged.

West Virginia's pending bill list is cleared. HB 4626 was vetoed and SB 906 is already enacted as the state's trigger law.

Armenia is now recorded as mixed. Small amounts are an administrative offense, while larger quantities remain a criminal offense.

Croatia's record now cites the official gazette. The decriminalized status is unchanged.

Oregon's pending bill list is cleared. HB 4040 is enacted and HB 4110 died in committee.

The FDA issued final guidance on how psychedelic drugs should be studied in clinical trials, replacing the draft it published in 2023. Guidance sets out what the agency expects; it does not carry the force of law (91 FR 43101).

The FDA set a public hearing on the possible future medical use of psychedelic drugs for 14 Sep 2026 and began taking written comments. Anyone wanting to attend or ask to speak must register by 21 Aug 2026 (91 FR 43095).

Since then: The hearing was held on 14 Sep 2026; the FDA streamed it live.

The Health Resources and Services Administration asked the public how psychedelic treatments should be staffed and delivered in outpatient clinics if any are ever approved, with comments closing 13 Aug 2026 (91 FR 43103).

The supporting citation for HB 2218 moves from a bill-tracking site to the Kansas Legislature's own note on the bill. We use trackers to find bills and official pages to say what they contain.

The entry now cites Montana's own Schedule I listing at section 50-32-222 rather than a bill-tracking page. State records confirm LC 1208 was the draft number for HB 955.

The entry had linked to a bill-tracking site. It now links to the Rhode Island General Assembly's own text of H 7756. Trackers are useful for finding a bill; the legislature is what we cite.

Oregon's psilocybin program laid out its 2026 rule changes: proposed rules publish 1 Sep 2026 and restructure all fees, including ending reduced fees. Public comment runs 1 to 21 Sep, with hearings 15 and 16 Sep. The program's legal status is unchanged.

Since then: The fee increases were dropped on 22 Sep 2026.

Louisiana's psychedelic-assisted therapy initiative became law as Act 956. It takes effect August 1, 2026.

New Mexico's clinical-practice committee has adopted a standard for the preparation sessions a patient has before psilocybin treatment, requiring that they be one-to-one rather than delivered to a group. The committee advises the health department; it does not make rules, and the rule that would govern practitioners is still only proposed.

Poland's illegal status was confirmed against the full text of the 2005 drug Act. Article 62a lets prosecutors drop small-amount cases at their discretion, which is not decriminalization. A widely repeated claim that Poland passed a medical psilocybin reform in 2026 was checked and rejected; it appears to confuse Poland with Czechia.

Ireland's entry had cited a hemp order by mistake. It now cites the Misuse of Drugs Regulations 2017 and the 2006 order that brought psilocybin mushrooms within the law. Possession for personal use is a criminal offence, as recorded.

Greece was confirmed illegal, and a widely repeated online claim that the country runs a state medical prescribing program was checked and found to have nothing behind it.

Pakistan's listing was checked against the government's own text of the Control of Narcotic Substances Act. Schedule-I names psilocybine at entry 69, and section 6 permits only medical, scientific or industrial use.

Argentina was moved out of the decriminalized column. The statute still makes possession a crime, and the Supreme Court's 2009 ruling is applied case by case rather than across the board.

An early review recorded small-amount possession as an administrative offense, drawing on a campaigners' map rather than Armenia's own text. The criminal code could not be read at the time, so no effective date was set.

Checked, with no change found. A 2026 consultation may widen who is allowed to prescribe under Australia's Authorised Prescriber scheme, but psilocybine's Schedule 8 listing for treatment-resistant depression is what it has been since 2023.

Austria was filed as having decriminalized possession. It has not: possession is a criminal offense that prosecutors may divert into probation and treatment, and the status was corrected to illegal.

A full-text check of the Bahamas statute portal found psilocybin absent from the Dangerous Drugs Act, though LSD was listed there, so nothing in the entry changed at this review.

Belgium was listed as decriminalized and it is not. The 1921 law itself puts possession at three months to five years in prison, so the status was corrected to illegal.

Bolivia had been recorded as legal on the strength of an entry that was actually about ayahuasca. Ley 1008 lists psilocybin, and the status was corrected to illegal.

Brazil had been recorded as legal. It is not. Psilocybin and psilocin are prohibited under Lista F2 of Portaria 344/1998, the mushrooms themselves are unlisted, and the courts are split on what that means, so the status is corrected to mixed.

Canada's medical access route was checked and left as it stood. Two things had moved around it during 2025: approvals slowed under a new government, and the Federal Court of Appeal ruled in June 2025 on exemptions for practitioners training to deliver the therapy.

Chile's decriminalized status was confirmed against the official text of Ley 20.000. Personal use stays outside the trafficking offense and nothing in the entry changed.

Colombia's status was confirmed, and the entry gained the three instruments that actually produce it: the 1994 judgment, the 2012 judgment that kept the trafficking offense alive, and the December 2023 repeal of the police fines for personal-dose possession.

Costa Rica's decriminalized status was confirmed: Ley 8204 attaches no penalty to personal consumption. The entry gained the caveat that the statute sets no quantity threshold at all.

Croatia's decriminalization dates from when the amendments took effect on 1 January 2013, not from the December day parliament passed them. The date shown is corrected.

Czechia's prescribing scheme was confirmed in force from 1 Jan 2026, and the entry now cites the act and the December 2025 decree that create it. The first treatments were expected in the second half of 2026.

Denmark had been recorded as mixed, which overstated the position. Possession is criminal, the only exceptions are for research, and no medical program exists, so the status moves to illegal.

Ecuador's entry rested on quantity tables that had already been repealed in November 2023. Consumption is still constitutionally protected, but with no threshold left, possession is judged case by case, so the status moved to mixed.

Estonia's misdemeanor regime was confirmed, and a draft Penal Code amendment that would treat dependent users differently from dealers was added to the entry.

Finland had been marked mixed, on the strength of an unsettled question about ayahuasca. That says nothing about psilocybin, which is a criminal narcotics offense in Finland, so the status is corrected to illegal.

France was filed as having decriminalized drug use. The fine police can issue on the spot is a criminal penalty for a criminal offense, and a law of June 2025 hardened enforcement, so the status was corrected to illegal.

Germany's compassionate use program was confirmed active and unchanged, though the regulator's psilocybin-specific listing could not be read directly at this review.

Iceland had been recorded as mixed on the theory that freshly picked mushrooms fell outside the ban. Regulation 233/2001 draws no such line, so the status was corrected to illegal.

Israel's entry claimed a medical route that does not exist. Psilocybin is approved for no indication there and reachable only through clinical trials, so the status was corrected to illegal.

Italy's decriminalized status was confirmed: personal possession is an administrative offense under article 75 of DPR 309/1990, not a crime.

Jamaica's status held. The health ministry's 2024 warning about psilocybin products, and public calls to amend the Dangerous Drugs Act, changed no law, and a weak source was dropped from the entry.

Latvia's decriminalized status was confirmed. Small-amount possession draws a warning or a fine of up to EUR 280, while larger quantities stay criminal.

Lithuania had been listed as decriminalized. Since 2017 possessing even a small quantity has been a criminal matter under Article 259(2) of the Criminal Code, so the status is corrected to illegal.

Mexico's small-quantity rule works off a dose table that leaves psilocybin out. Possession still carries four to seven and a half years, with one narrow exemption for indigenous and Afro-Mexican ceremonies, so the status moved from decriminalized to illegal.

Psilocybin is not named in Nepal's Narcotic Drugs (Control) Act, 2033 (1976). That leaves it unscheduled rather than permitted, and the entry stays recorded as mixed.

The Netherlands entry now points at the Dutch legal texts themselves, after the government link it had been citing stopped working. Truffles are unaffected, and a viral claim about a January 2026 mushroom fine was checked and found to be false.

New Zealand had been recorded as decriminalized, which was wrong: psilocybin is a Class A drug. The status was corrected to medical because Medsafe began approving individual prescribers in 2025.

North Macedonia had been listed as decriminalized. Drug use is a fine-only misdemeanor there, but possession is treated as criminal and is prosecuted in practice, and the available sources contradict each other on where the line sits. The status is changed to mixed.

Norway's entry described a reform as pending. Parliament voted the decriminalization bill down in June 2021 and the 2025 reform keeps the ban in place, so the status was corrected to illegal.

Peru had been recorded as legal, which was wrong. The personal-use exemption in article 299 does not name psilocybin, and the cultural-heritage declaration covers ayahuasca and nothing else, so the status was corrected to illegal.

The source this entry pointed at had gone dead, so the entry was marked for a replacement. Nothing about the law changed: Portugal's decriminalization regime under Law 30/2000 stands as it has since 2001.

Slovenia's entry was checked and its decriminalized listing held: possession for personal use is a minor offense rather than a crime.

Spain's status was confirmed at the official gazette: personal possession is not a crime, and consuming or possessing in public is an administrative infraction under article 36.16 of Ley Organica 4/2015.

St. Vincent and the Grenadines had been recorded as legal. What is described is a licensing scheme for medicinal and research use, not a general legalization, so the status was narrowed to medical.

Sweden had been recorded as decriminalized. The Narkotikastrafflag makes personal use itself a crime, so the status was corrected to illegal.

Switzerland's entry now rests on the Federal Office of Public Health's own page rather than a law firm article, and the 2024 program figures are brought up to date. The status is unchanged.

Thailand's entry was citing a narcotics act that had been repealed. It now cites the Narcotics Code of 2021 that replaced it, together with the 2024 notification allowing psilocybin only in approved medical treatment and research. The status did not change.

Ukraine's decriminalized status was confirmed: possession of a small amount is an administrative offense. The entry now cites article 44 of the Code of Administrative Offenses and article 309 of the Criminal Code, and records a 2025 health ministry proposal to open the substances to research.

The United Kingdom's status held at Class A and Schedule 1. The entry now cites GOV.UK directly, and records two things in motion: the July 2025 trial of lighter research licensing, and the psilocybin review the government asked its drugs advisory council to carry out.

Uruguay had been recorded as legal, which overstated it. Personal-use possession is exempt from liability under article 31 of Decreto-Ley 14.294, but sale and production are still crimes, so the status moves to decriminalized.

A task force report and a ballot campaign are not a law. Alaska has enacted nothing, and the entry was corrected from mixed to illegal.

Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.

California's status was confirmed and its bill list updated: SB 751 was dead by May 2025, and AB 2489 was alive but held in the Assembly Appropriations suspense file in May 2026.

Checked, with no change found. About 34 healing centers were licensed at the time of this review, and a statutory trigger dated 1 Jun 2026 opens the question of whether Colorado's program should extend beyond psilocybin.

Connecticut widened its psilocybin pilot: a law signed on 4 June 2026 opened it beyond veterans and first responders to adults generally. A separate 2025 bill to decriminalize possession passed the House and died in the Senate.

Florida had been marked mixed. Nothing in the record pulls the other way: possession is a felony and the state tightened the law again in 2025, so the status is corrected to illegal. No reform moved in 2026.

Georgia's two 2026 psychedelic laws do not let anyone use psilocybin: one waits on federal approval, the other regulates clinics. The entry now reads illegal.

Hawaii moves from mixed to illegal. Everything the state has done is a study or a task force, and no access or decriminalization measure has been enacted.

Illinois had been recorded as mixed. Its only psilocybin activity is an advisory board bill and a stalled CURE Act, neither enacted, so the status moved to illegal.

Indiana had been marked mixed. The only thing the state has enacted is a research fund, which pays for studies and opens no route for patients, so the status is corrected to illegal.

Both of Iowa's psilocybin bills failed, one by veto in 2025 and one for want of a Senate vote in May 2026. With nothing enacted, the entry was corrected from mixed to illegal.

Kansas moves from mixed to illegal. Its only psilocybin bill, which depended on a future FDA approval, stalled on the House calendar and died without becoming law.

Kentucky had been recorded as mixed on the strength of a law that is about ibogaine, not psilocybin. Senate Bill 77 changes nothing for psilocybin, so the status was corrected to illegal.

Louisiana's mixed status was confirmed. SB 43, the psychedelic therapy initiative, had passed both chambers unanimously and was sitting on the governor's desk as of June 1, 2026.

Maine had been marked mixed on the strength of a decriminalization bill. LD 1034 failed its final enactment votes and died on June 10, 2025, so the status is corrected to illegal.

The only psychedelics measure Maryland has enacted extends a task force. That is not access, and the entry was corrected from mixed to illegal.

Massachusetts stays recorded as decriminalized. The list of pending bills was updated: H.4986 now consolidates two earlier bills, H.2506 and H.2532, and sits in the Health Care Financing committee unenacted.

Michigan's status held. The bill listed as pending had long since died and was replaced with HB 4686, introduced in 2025 and sitting in committee, and a source that covered only cannabis was swapped out.

Minnesota's mixed status was confirmed. HF 2906 had moved further than the entry showed, clearing a House committee in March 2026, but it was still unenacted when the biennium closed.

Mississippi's two 2026 laws leave psilocybin where it was: one funds ibogaine trials, the other takes effect only if the federal government moves first. The status is corrected from mixed to illegal.

Missouri's psilocybin bills all stopped at the study stage, and the fate of the one the House passed in April 2026 was still unresolved at the time. The entry was corrected from mixed to illegal.

Montana moves from mixed to illegal. The only activity on record is HB 955, defeated in committee in 2023, and the legislature does not sit in regular session in 2026.

Nevada had been recorded as mixed on the strength of a working group that only studies the question. With the AB 378 pilot dead at the end of the 2025 session, nothing enacted opens access, so the status moved to illegal.

Every New Hampshire reform bill of 2025 and 2026 is dead. HB 528 was tabled in June 2025, HB 1796 was killed in February 2026, and the Senate killed HB 1809 on May 5, 2026. The status is corrected from mixed to illegal.

New Jersey's hospital pilot was confirmed, and the signing date was corrected from 16 January to 20 January 2026.

New Mexico stays recorded as medical. The state has moved its target for patient access forward to December 2026, a year earlier than planned, and an equity fund has been added.

New York had been recorded as mixed because reform bills exist. None of them has had a committee vote, and a pending bill changes no law, so the status was corrected to illegal.

North Carolina had been recorded as mixed. SB 568 was a study bill and it died at the May 2025 crossover deadline, so the status moved to illegal.

Nothing enacted, no city measure, and no bill moving in the current General Assembly. Ohio's entry was corrected from mixed to illegal.

Oklahoma moves from mixed to illegal. The only psychedelics law enacted in 2026 covers ibogaine, and no psilocybin bill was enacted.

Oregon's status held. HB 4040, which widens who may be licensed as a facilitator, became law in April 2026, and the ibogaine bill HB 4110 died in committee, so neither is listed as pending any more.

Pennsylvania had been recorded as mixed. SB 1149 has never left the committee it was referred to and the older research bills are dead, so the status moved to illegal.

Rhode Island had been marked mixed. H 7756 was withdrawn at its sponsor's request on April 9, 2026 and nothing has been enacted, so the status is corrected to illegal.

South Dakota moves from mixed to illegal. HB 1099 was signed in March 2026, but its carve-out only applies once the FDA approves a psilocybin product, so it grants no access today.

Tennessee had been recorded as mixed on the basis of a law that names only ibogaine. No psilocybin legislation exists in the state, so the status was corrected to illegal.

Texas had been recorded as mixed because the state funds psychedelic research. Funding is not access, so the status moved to illegal. SB 2308's effective date was corrected to 11 June 2025, and the state announced in March 2026 that it would run the ibogaine trials itself.

Utah's entry now records HB 390 (2026), which authorizes a study of psychedelic-assisted therapy for veterans, and the effective date of the 2024 clinical authorization is corrected to May 1, 2024. The status is unchanged.

Vermont's own advisory group recommended against creating a program, and the bill that followed it never moved. The listing changed from mixed to illegal.

Virginia moves from mixed to illegal. Its two trigger laws were enacted in April 2026 but stay dormant until the FDA approves a psilocybin product, and a separate bill to create an advisory council, SB 1101, was killed in the House.

Washington's status held. The medical program bill SB 5921 got further than earlier attempts and then died in the Ways and Means committee in February 2026.

West Virginia had been recorded as mixed. SB 906 is enacted but does nothing until the FDA acts, HB 4626 was vetoed, and a third bill had been listed under the wrong number, so the status moved to illegal.

The DC entry carried the wrong law number and the wrong effective date. It is D.C. Law 23-268, effective 16 March 2021. The status itself was confirmed.

The British Virgin Islands had been recorded as legal, which the statute does not support: it schedules psilocin and its esters and makes possession an offence. The gap around unlisted fresh mushrooms is real, so the status moved to mixed.

Colorado enacted HB 26-1325, which adds an ibogaine research pilot to the state natural medicine program. It takes effect August 12, 2026.

Chile changed its drug law in May 2026. The change could expose small amounts of psilocybin to a trafficking penalty, but it depends on a new list the government has not published yet.

Tennessee's entry now records that the ibogaine HOPE Treatment Act was signed on 22 May 2026 and became Public Chapter 1119. It does not concern psilocybin, whose status is unchanged.

Oklahoma's entry now records the ibogaine Breakthrough Therapy Act as enacted rather than pending, and cites the enrolled text of the act. Psilocybin's status is unchanged.

The FDA issued three national priority vouchers to psychedelic drug programs, two of them for psilocybin. A voucher speeds up FDA review; it does not approve a drug or change its legal schedule (24 Apr 2026).

The President signed Executive Order 14401, directing the FDA and the Drug Enforcement Administration to speed up psychedelic drug review, build an early access route for seriously ill patients, and consider rescheduling once a drug finishes Phase 3 trials. As of this review the access route has not been set up (91 FR 21709).

Analysis: the order's access route

Utah's entry now records the 2026 scheduling act that would follow a federal rescheduling of an approved psilocybin medicine, and corrects the description of the veterans research law, which authorizes a study but appropriates no money itself.

The DEA set the quantities of psilocybin and psilocyn that registered researchers and manufacturers may legally produce in the United States during 2026 (91 FR 287).

Pennsylvania's entry now records both psilocybin bills before the General Assembly, HB 1439 as well as SB 1149. Neither has moved and the legal position is unchanged.

Vermont's entry now records all three psychedelic bills before the General Assembly, and cites the statute that prohibits psilocybin rather than the advisory working group. Nothing in Vermont law has changed.

Psilocybin and psilocyn became Schedule I controlled substances when the Controlled Substances Act took effect on 1 May 1971 (21 U.S.C. 812).